Palatin Technologies, Inc. (NYSE American: PTN) is a specialized biopharmaceutical company. PTN develops first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Our product and product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Learn more about Palatin Technologies here: https://www.palatin.com/

Vyleesi®, our FDA-approved product, is the first and only on-demand treatment of acquired, generalized, hypoactive sexual desire disorder (HSDD), affecting 1 in 10 pre-menopausal women. Vyleesi® was approved by the Food and Drug Administration (FDA) in June 2019. We have licensed Chinese rights to Shanghai Fosun Pharmaceutical Industrial Development Co., Ltd. and Korean rights to Kwangdong Pharmaceutical Co., Ltd. We also have development programs or drug candidates for inflammatory disease indications, heart failure and fibrosis.

To learn more about acquired, generalized, hypoactive sexual desire disorder (HSDD), visit here: https://www.unblush.com/